Biosimilars are the fastest growing segment fueling the growth of the Insulin Glargine Market

 The global Insulin Glargine Market is estimated to be valued at US$ 6,178.14 Mn in 2023 and is expected to exhibit a CAGR of 0.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Insulin glargine is a long-acting recombinant human insulin analog used for the treatment of diabetes mellitus. Its advantages include providing continuous basal insulin levels for 24 hours, reduced risk of hypoglycemia, and improved glycemic control. Insulin glargine is mostly prescribed by doctors for Type 1 and Type 2 diabetes patients who require insulin injections to control blood glucose levels.

Market key trends:
Growing geriatric population suffering from diabetes is a key factor driving the insulin glargine market growth. According to WHO, by 2050, the number of people aged 60 years and older will total 2 billion, up from 900 million in 2015. Older adults are more prone to develop diabetes owing to weakened immune system and decreased glucose tolerance with aging. Increased research into novel formulations of insulin glargine having enhanced pharmacokinetics is another trend observed in recent years. Drug makers are developing formulations to provide optimum insulin release for longer duration to boost efficacy and improve convenience and compliance for patients.

Segment Analysis
The global insulin glargine market is segmented based on type, distribution channel, and region. Based on type, the market is divided into prefilled syringes and vials. Among these, the prefilled syringes segment dominates the market and accounts for the largest revenue share. Prefilled syringes offers greater convenience of use and reduces risk of dosing errors. Based on distribution channel, the market is bifurcated into retail pharmacies and hospital pharmacies. Retail pharmacies dominate the market as insulin glargine prescriptions are generally purchased from retail pharmacies.

Key Takeaways
The Global Insulin Glargine Market Size is expected to reach US$ 6,260.64 Mn by 2030, expanding at a CAGR of 0.2% over the forecast period. The growth can be attributed to the increasing prevalence of diabetes globally. Regionally, North America holds the highest share in the global market and is expected to maintain its dominance over the forecast period. This is due to the growing geriatric population and rising healthcare expenditures in the region. Key players operating in the insulin glargine market are Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others. Eli Lilly dominates the market owing to its innovative product portfolio and strong distribution network both at global and regional level.

Regional Analysis
North America dominates the global insulin glargine market with the highest market share. This can be attributed to growing geriatric population suffering from diabetes and rising healthcare expenditures. Europe holds the second largest share in the global market. However, Asia Pacific is expected to exhibit the highest growth over the forecast period owing to increasing prevalence of diabetes and improving access to insulin therapies in major Asian countries such as India and China.

Key Players Analysis
Key players operating in the insulin glargine market are Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS. Eli Lilly dominates the market owing to its wide portfolio of insulin analogs and strong distribution network. The company is continuously investing in R&D to launch next-generation insulin products and strengthen its market position globally.

 

Read more: https://www.ukwebwire.com/insulin-glargine-market-insights-trends/

Comments

Post a Comment

Popular posts from this blog

Vegan Yogurt Market is Poised for Growth Driven by Rising Health Consciousness

Image
Vegan yogurt is a dairy-free alternative to conventional yogurt made from plant-based milk such as soy, almond, oat, coconut or rice. It provides similar texture and taste to dairy yogurt but without any animal products.Vegan yogurt offers several health advantages over dairy yogurt as it is devoid of lactose, cholesterol and saturated fats. The growing number of people adopting vegan and flexitarian diets has driven the demand for plant-based dairy alternatives like vegan yogurt. The global vegan yogurt market is estimated to be valued at US$ 4.15 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031. Key Takeaways Key players- Met Fods, Cocos Organic, Hain Celestial, EasiYo Product Limited, Danone, General Mills Inc., Stonyfield Far, Inc., Daiya Foods Inc.m Good Karma foods, Inc.m Hudson River Foodsm NANCY'S, Kite Hill, COYO Pty lTd., Nush Foods, Chobani, LLC, Barambah Oraganics Pty Ltd., Blue Diamond Growers, Dean Foodsm General Mills Inc...
Read more

Hypoglycemic Drugs Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Diabetes in the Geriatric Population

Image
Hypoglycemic drugs or anti-diabetic drugs are medications used to treat diabetes mellitus by lowering blood glucose levels. Some key hypoglycemic drugs include insulin, sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists. These drugs help control blood sugar levels in diabetics and prevent or delay diabetes-related health complications. The global hypoglycemic drugs market is estimated to be valued at US$ 720.72 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growth of the global hypoglycemic drugs market is majorly driven by the increasing prevalence of diabetes in the geriatric population globally. As per estimates, around 1 in every 11 people aged 65 years and above have diabetes. Further, the number of people with diabetes in this age group is anticipated to grow from 25.9 million in 2017 to...
Read more

Clinical Trials Rising with Digital Technologies Adoption

Image
 Clinical trials support services play a vital role in assisting sponsors and life science companies to conduct clinical trials in a precise and well-organized manner.These services assist pharmaceutical companies in patient recruitment, data management, site management, and overall clinical trial management. With rising complexities in clinical trials owing to integration of technologies like telehealth and remote patient monitoring, the demand for these support services is growing substantially. The global Clinical Trials Support Services Market is estimated to be valued at US$ 22.38 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The growing adoption of digital technologies across clinical trials is a key trend accelerating the growth of the clinical trials support services market. Digital tools like electronic data capture, clinical trial manag...
Read more